FDA signals uptick in enforcement with market sweep on depression claims | Hogan Lovells
On 19 February, 2021 the U.S. Food and Drug Administration (FDA) announced warning letters to ten companies for selling dietary supplements that claim to cure, treat, mitigate, or prevent depression and other mental health disorders in violation of the Federal Food, Drug, and Cosmetic Act. We expect the action signals that FDA labeling enforcement on […]
FDA signals uptick in enforcement with market sweep on depression claims | Hogan Lovells Read More »